Cited by 892Cancer Cells and MetastasisAcute Lymphoblastic Leukemia researchDrug Transport and Resistance Mechanisms

The DOI matches its Crossref record; 109 of the 109 references it cites were found in a registry or an index.

Environment-mediated drug resistance: a major contributor to minimal residual disease

Meads, Mark B., Gatenby, Robert A., Dalton, William S.·2009·Nature Reviews Cancer

Open this paper in CoChat — free account

Abstract

Environment-mediated drug resistance is a form of de novo drug resistance that protects tumour cells from the initial effects of diverse therapies. Surviving foci of residual disease can then develop complex and permanent acquired resistance in response to the selective pressure of therapy. Recent evidence indicates that environment-mediated drug resistance arises from an adaptive, reciprocal signalling dialogue between tumour cells and the surrounding microenvironment. We propose that new therapeutic strategies targeting this interaction should be applied during initial treatment to prevent the emergence of acquired resistance.

Integrity signals

Registry

Crossref · 10.1038/nrc2714

Cites

109 of 109 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Stromal Fibroblasts Present in Invasive Human Breast Carcinomas Promote Tumor Growth and Angiogenesis through Elevated SDF-1/CXCL12 Secretion
Orimo, A., Gupta, P. B., Sgroi, D. C., Arenzana-Seisdedos, F., Delaunay, T., Naeem, R., Carey, V. J., Richardson, A. L., & Weinberg, R. A. (2005) · Cell · doi:10.1016/j.cell.2005.02.034 · Cited by 3,759
Treatment of Acute Lymphoblastic Leukemia
Pui, C., & Evans, W. E. (2006) · New England Journal of Medicine · doi:10.1056/nejmra052603 · Cited by 2,012
Bortezomib plus Melphalan and Prednisone for Initial Treatment of Multiple Myeloma
San Miguel, J. F., Schlag, R., Khuageva, N. K., Dimopoulos, M. A., Shpilberg, O., Kropff, M., Spicka, I., Petrucci, M. T., Palumbo, A., Samoilova, O. S., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0801479 · Cited by 1,899
Stromal Gene Signatures in Large-B-Cell Lymphomas
Lenz, G., Wright, G. W., Davé, S. S., Xiao, W., Powell, J. I., Zhao, H., Xu, W., Tan, B. T., Goldschmidt, N., Iqbal, J., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802885 · Cited by 1,847
Stimulation of Bone Formation in Vitro and in Rodents by Statins
Mundy, G. R., Garrett, R., Harris, S., Chan, J., Chen, D., Rossini, G., Boyce, B. F., Zhao, M., & Gutierrez, G. (1999) · Science · doi:10.1126/science.286.5446.1946 · Cited by 1,776
Stromal gene expression predicts clinical outcome in breast cancer
Finak, G., Bertos, N., Pepin, F., Sadekova, S., Souleimanova, M., Zhao, H., Chen, H., Ömeroğlu, G., Meterissian, S. H., Ömeroğlu, A., et al. (2008) · Nature Medicine · doi:10.1038/nm1764 · Cited by 1,707
Constitutive Activation of Stat3 Signaling Confers Resistance to Apoptosis in Human U266 Myeloma Cells
Catlett-Falcone, R., Landowski, T. H., Oshiro, M. M., Turkson, J., Levitzki, A., Savino, R., Ciliberto, G., Moscinski, L., Fernández-Luna, J. L., Nuñez, G., et al. (1999) · Immunity · doi:10.1016/s1074-7613(00)80011-4 · Cited by 1,638
Self-citation
Reversion of the Malignant Phenotype of Human Breast Cells in Three-Dimensional Culture and In Vivo by Integrin Blocking Antibodies
Weaver, V. M., Petersen, O. W., Wang, F., Larabell, C. A., Briand, P., Damsky, C., & Bissell, M. J. (1997) · The Journal of Cell Biology · doi:10.1083/jcb.137.1.231 · Cited by 1,483
A Pooled Analysis of Bone Marrow Micrometastasis in Breast Cancer
Braun, S., Vogl, F. D., Naume, B., Janni, W., Osborne, M. P., Coombes, R. C., Schlimok, G., Diel, I., Gerber, B., Gebauer, G., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050434 · Cited by 1,380
DQIS — Distributed Quorum-Based Independent Immune Surveillance: A Theoretical Framework for Byzantine Fault Tolerance for Multi-Channel Immune Surveillance
DQIS Research Group (2026) · PubMed · doi:10.5281/zenodo.21937949 · Cited by 1,333

Flagged first, then by citations

Show all 109 references

Research works printed but not linked: 1

Goldie, J. H. & Coldman, A. J. A mathematic model for relating the drug sensitivity of tumors to their spontaneous mutation rate. Cancer Treat Rep. 63, 1727–1733 (1979).

Sorted by citations

Cancer nanomedicine: progress, challenges and opportunities
Shi, J., Kantoff, P. W., Wooster, R., & Farokhzad, O. C. (2017) · Nature Reviews Cancer · doi:10.1038/nrc.2016.108 · Cited by 5,873
The biology and function of fibroblasts in cancer
Kalluri, R. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2016.73 · Cited by 4,366
Influence of tumour micro-environment heterogeneity on therapeutic response
Junttila, M. R., & de Sauvage, F. J. (2013) · Nature · doi:10.1038/nature12626 · Cited by 2,694
The causes and consequences of genetic heterogeneity in cancer evolution
Burrell, R. A., McGranahan, N., Bartek, J., & Swanton, C. (2013) · Nature · doi:10.1038/nature12625 · Cited by 2,262
Intra-tumour heterogeneity: a looking glass for cancer?
Marusyk, A., Almendro, V., & Polyák, K. (2012) · Nature reviews. Cancer · doi:10.1038/nrc3261 · Cited by 2,058
Tumor microenvironment and therapeutic response
Wu, T., & Dai, Y. (2017) · Cancer Letters · doi:10.1016/j.canlet.2016.01.043 · Cited by 1,802
Macrophages and Therapeutic Resistance in Cancer
Ruffell, B., & Coussens, L. M. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.02.015 · Cited by 1,474
Clinical and therapeutic relevance of cancer-associated fibroblasts
Chen, Y., McAndrews, K. M., & Kalluri, R. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00546-5 · Cited by 1,230
CD10+GPR77+ Cancer-Associated Fibroblasts Promote Cancer Formation and Chemoresistance by Sustaining Cancer Stemness
Su, S., Chen, J., Yao, H., Liu, J., Yu, S., Lao, L., Wang, M., Luo, M., Xing, Y., Chen, F., et al. (2018) · Cell · doi:10.1016/j.cell.2018.01.009 · Cited by 1,230
DNA damage response signaling pathways and targets for radiotherapy sensitization in cancer
Huang, R., & Zhou, P. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-0150-x · Cited by 1,288
Exosomes in cancer development, metastasis, and drug resistance: a comprehensive review
Azmi, A. S., Bao, B., & Sarkar, F. H. (2013) · Cancer and Metastasis Reviews · doi:10.1007/s10555-013-9441-9 · Cited by 1,185
Microtubules and resistance to tubulin-binding agents
Kavallaris, M. (2010) · Nature reviews. Cancer · doi:10.1038/nrc2803 · Cited by 1,134
Intratumor Heterogeneity: The Rosetta Stone of Therapy Resistance
Marusyk, A., Janiszewska, M., & Polyak, K. (2020) · Cancer Cell · doi:10.1016/j.ccell.2020.03.007 · Cited by 1,009
Fibroblast heterogeneity in the cancer wound
Öhlund, D., Elyada, E., & Tuveson, D. A. (2014) · The Journal of Experimental Medicine · doi:10.1084/jem.20140692 · Cited by 982
How the ageing microenvironment influences tumour progression
Fane, M., & Weeraratna, A. T. (2020) · Nature Reviews Cancer · doi:10.1038/s41568-019-0222-9 · Cited by 849
Effect of exosomal miRNA on cancer biology and clinical applications
Sun, Z., Shi, K., Yang, S., Liu, J., Zhou, Q., Wang, G., Song, J., Li, Z., Zhang, Z., & Yuan, W. (2018) · Molecular Cancer · doi:10.1186/s12943-018-0897-7 · Cited by 800
Tumor microenvironment: Sanctuary of the devil
Hui, L., & Chen, Y. (2015) · Cancer Letters · doi:10.1016/j.canlet.2015.07.039 · Cited by 797
Cancer-Associated Fibroblasts: Their Characteristics and Their Roles in Tumor Growth
Shiga, K., Hara, M., Nagasaki, T., Sato, T., Takahashi, H., & Takeyama, H. (2015) · Cancers · doi:10.3390/cancers7040902 · Cited by 774
Microenvironmental regulation of therapeutic response in cancer
Klemm, F., & Joyce, J. A. (2014) · Trends in Cell Biology · doi:10.1016/j.tcb.2014.11.006 · Cited by 789
Exosome mediated communication within the tumor microenvironment
Milane, L. S., Singh, A., Mattheolabakis, G., Suresh, M., & Amiji, M. M. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.06.029 · Cited by 752
Carcinoma-associated fibroblasts: orchestrating the composition of malignancyPreprint
Gascard, P. D., & Tlsty, T. D. (2016) · Genes & Development · doi:10.1101/gad.279737.116 · Cited by 767
Metabolic Reprogramming: the Emerging Concept and Associated Therapeutic Strategies
Yoshida, G. J. (2015) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-015-0221-y · Cited by 716
Mechanisms and insights into drug resistance in cancer
Zahreddine, H. A., & Borden, K. L. B. (2013) · Frontiers in Pharmacology · doi:10.3389/fphar.2013.00028 · Cited by 680
The Wnt signaling pathway in cancer
Duchartre, Y., Kim, Y., & Kahn, M. (2015) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2015.12.005 · Cited by 558
Tumor Microenvironment Complexity: Emerging Roles in Cancer Therapy
Swartz, M. A., Iida, N., Roberts, E. W., Sangaletti, S., Wong, M. H., Yull, F. E., Coussens, L. M., & DeClerck, Y. A. (2012) · Cancer Research · doi:10.1158/0008-5472.can-12-0122 · Cited by 542
Imaging Tumor-Stroma Interactions during Chemotherapy Reveals Contributions of the Microenvironment to Resistance
Nakasone, E. S., Askautrud, H. A., Kees, T., Park, J.-H., Plaks, V., Ewald, A. J., Fein, M. R., Rasch, M. G., Tan, Y.-X., Qiu, J., et al. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.02.017 · Cited by 485
Genetic heterogeneity and cancer drug resistance
Turner, N. C., & Reis-Filho, J. S. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70335-7 · Cited by 460
Molecular aspects of cancer cell resistance to chemotherapy
Rebucci, M., & Michiels, C. (2013) · Biochemical Pharmacology · doi:10.1016/j.bcp.2013.02.017 · Cited by 423
Leukemia Stem Cells and Microenvironment: Biology and Therapeutic Targeting
Konopleva, M. Y., & Jordan, C. T. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.31.0904 · Cited by 411
Resistance Mechanisms to Anti-angiogenic Therapies in Cancer
Haibe, Y., Kreidieh, M., Hajj, H. E., Khalifeh, I. M., Mukherji, D., Temraz, S. N., & Shamseddine, A. I. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.00221 · Cited by 430
Targeting lysyl oxidase (LOX) overcomes chemotherapy resistance in triple negative breast cancer
Saatci, Ö., Kaymak, A., Raza, U., Ersan, P. G., Akbulut, Ö., Banister, C. E., Sikirzhytski, V., Tokat, Ü. M., Aykut, G., Ansari, S. A., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-16199-4 · Cited by 390
Nuclear export of proteins and drug resistance in cancer
Turner, J. G., Dawson, J. L., & Sullivan, D. M. (2011) · Biochemical Pharmacology · doi:10.1016/j.bcp.2011.12.016 · Cited by 353
Resistance to Anti-Angiogenic Therapy in Cancer—Alterations to Anti-VEGF Pathway
Itatani, Y., Kawada, K., Yamamoto, T. S., & Sakai, Y. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19041232 · Cited by 364
Fibroblast-Derived Exosomes Contribute to Chemoresistance through Priming Cancer Stem Cells in Colorectal Cancer
Hu, Y., Yan, C., Mu, L., Huang, K., Li, X., Tao, D., Wu, Y., & Qin, J. (2015) · PLoS ONE · doi:10.1371/journal.pone.0125625 · Cited by 352
Doxorubicin resistance in breast cancer cells is mediated by extracellular matrix proteins
Lovitt, C. J., Shelper, T., & Avery, V. M. (2018) · BMC Cancer · doi:10.1186/s12885-017-3953-6 · Cited by 358
Drug resistance in metastatic castration-resistant prostate cancer
Šeruga, B., Ocaña, A., & Tannock, I. F. (2010) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2010.136 · Cited by 346
Focal adhesion signaling and therapy resistance in cancer
Eke, I., & Cordes, N. (2014) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2014.07.009 · Cited by 331
Tumor-Host Interactions: A Far-Reaching Relationship
McAllister, S. S., & Weinberg, R. A. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.28.4257 · Cited by 333
Diverse marrow stromal cells protect CLL cells from spontaneous and drug-induced apoptosis: development of a reliable and reproducible system to assess stromal cell adhesion-mediated drug resistance
Kurtova, A. V., Balakrishnan, K., Chen, R., Ding, W., Schnabl, S., Quiroga, M. P., Sivina, M., Wierda, W. G., Estrov, Z. E., Keating, M. J., et al. (2009) · Blood · doi:10.1182/blood-2009-07-233718 · Cited by 319
Tumor microenvironment targeted nanotherapeutics for cancer therapy and diagnosis: A review
Thakkar, S., Sharma, D., Kalia, K., & Tekade, R. K. (2019) · Acta Biomaterialia · doi:10.1016/j.actbio.2019.09.009 · Cited by 321
Chemotherapy-enhanced inflammation may lead to the failure of therapy and metastasis
Vyas, D., Laput, G. P., & Vyas, A. K. (2014) · OncoTargets and Therapy · doi:10.2147/ott.s60114 · Cited by 316
Mesenchymal stem cells induce resistance to chemotherapy through the release of platinum-induced fatty acids
Roodhart, J. M. L., Daenen, L. G. M., Stigter, E. C. A., Prins, H.-J., Gerrits, J., Houthuijzen, J. M., Gerritsen, M. G., Schipper, H. S., Backer, M. J. G., van Amersfoort, M., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.08.010 · Cited by 305
Increased Lactate Secretion by Cancer Cells Sustains Non-cell-autonomous Adaptive Resistance to MET and EGFR Targeted Therapies
Apicella, M., Giannoni, E., Fiore, S., Ferrari, K. J., Fernández-Pérez, D., Isella, C., Granchi, C., Minutolo, F., Sottile, A., Comoglio, P. M., et al. (2018) · Cell Metabolism · doi:10.1016/j.cmet.2018.08.006 · Cited by 299
Tumor microenvironment promotes breast cancer chemoresistance
Mehraj, U., Dar, A. H., Wani, N. A., & Mir, M. A. (2021) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-020-04222-w · Cited by 294
Cytokines, Inflammation and Colon Cancer
Klampfer, L. (2011) · Current Cancer Drug Targets · doi:10.2174/156800911795538066 · Cited by 297
Fibroblast activation in cancer: when seed fertilizes soil
Kužet, S.-E., & Gaggioli, C. (2016) · Cell and Tissue Research · doi:10.1007/s00441-016-2467-x · Cited by 301
Implication of Tumor Microenvironment in Chemoresistance: Tumor-Associated Stromal Cells Protect Tumor Cells from Cell Death
Castells, M., Thibault, B., Delord, J., & Couderc, B. C. (2012) · International Journal of Molecular Sciences · doi:10.3390/ijms13089545 · Cited by 294
Targeting the Tumor Microenvironment: From Understanding Pathways to Effective Clinical Trials
Hua, F., & DeClerck, Y. A. (2013) · Cancer Research · doi:10.1158/0008-5472.can-13-0661 · Cited by 286
Advanced Cell Culture Techniques for Cancer Drug Discovery
Lovitt, C. J., Shelper, T., & Avery, V. M. (2014) · Biology · doi:10.3390/biology3020345 · Cited by 292
Mechanism-based cancer therapy: resistance to therapy, therapy for resistance
Ramos, P. M., & Bentires‐Alj, M. (2014) · Oncogene · doi:10.1038/onc.2014.314 · Cited by 287
Plasticity of tumour and immune cells: a source of heterogeneity and a cause for therapy resistance?
Hölzel, M., Bovier, A., & Tüting, T. (2013) · Nature reviews. Cancer · doi:10.1038/nrc3498 · Cited by 275
Cell adhesion-mediated mitochondria transfer contributes to mesenchymal stem cell-induced chemoresistance on T cell acute lymphoblastic leukemia cells
Wang, J., Liu, X., Qiu, Y., Shi, Y. X., Cai, J., Wang, B., Wei, X., Ke, Q., Sui, X. Y., Wang, Y., et al. (2018) · Journal of Hematology & Oncology · doi:10.1186/s13045-018-0554-z · Cited by 274
Microenvironment and tumor cell plasticity: An easy way out
Taddei, M. L., Giannoni, E., Comito, G., & Chiarugi, P. (2013) · Cancer Letters · doi:10.1016/j.canlet.2013.01.042 · Cited by 272
RETRACTED ARTICLE: Exosome-transmitted miR-128-3p increase chemosensitivity of oxaliplatin-resistant colorectal cancer
Liu, T., Zhang, X., Du, L., Wang, Y., Liu, X., Tian, H., Wang, L., Li, P., Zhao, Y., Duan, W., et al. (2019) · Molecular Cancer · doi:10.1186/s12943-019-0981-7 · Cited by 266
Retracted
The Untapped Potential of Ascites in Ovarian Cancer Research and Treatment
Ford, C. E., Werner, B., Hacker, N. F., & Warton, K. (2020) · British Journal of Cancer · doi:10.1038/s41416-020-0875-x · Cited by 261
Pharmacodynamic Drug–Drug Interactions
Niu, J., Straubinger, R. M., & Mager, D. E. (2019) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.1434 · Cited by 278
The intestinal microbiota, gastrointestinal environment and colorectal cancer: a putative role for probiotics in prevention of colorectal cancer?
Azcárate-Peril, M. A., Sikes, M. L., & Bruno-Bárcena, J. M. (2011) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00110.2011 · Cited by 260
The Emergence of Drug Transporter-Mediated Multidrug Resistance to Cancer Chemotherapy
Wu, C., Hsieh, C., & Wu, Y. (2011) · Molecular Pharmaceutics · doi:10.1021/mp200261n · Cited by 240
Multiple Myeloma: Available Therapies and Causes of Drug Resistance
Pinto, V., Bergantim, R., Caires, H. R., Seca, H., Guimarães, J. E., & Vasconcelos, M. H. (2020) · Cancers · doi:10.3390/cancers12020407 · Cited by 241
β1 Integrin/FAK/cortactin signaling is essential for human head and neck cancer resistance to radiotherapy
Eke, I., Deuse, Y., Hehlgans, S., Gurtner, K., Krause, M., Baumann, M. A., Shevchenko, A., Sandfort, V., & Cordes, N. (2012) · Journal of Clinical Investigation · doi:10.1172/jci61350 · Cited by 220
RETRACTED ARTICLE: Exosomal microRNA-32-5p induces multidrug resistance in hepatocellular carcinoma via the PI3K/Akt pathway
Fu, X., Liu, M., Qu, S., Ma, J., Zhang, Y., Shi, T., Wen, H., Yang, Y., Wang, S., Wang, J., et al. (2018) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-018-0677-7 · Cited by 217
Retracted
Therapeutic strategies targeting cancer stem cells
Yoshida, G. J., & Saya, H. (2015) · Cancer Science · doi:10.1111/cas.12817 · Cited by 222
Pharmacological targeting of the protein synthesis mTOR/4E‐BP1 pathway in cancer‐associated fibroblasts abrogates pancreatic tumour chemoresistance
Duluc, C., Moatassim-Billah, S., Chalabi‐Dchar, M., Perraud, A., Samain, R., Breibach, F., Gayral, M., Cordelier, P., Delisle, M., Bousquet, M., et al. (2015) · EMBO Molecular Medicine · doi:10.15252/emmm.201404346 · Cited by 218
Epithelial to Mesenchymal Transition: A Mechanism that Fuels Cancer Radio/Chemoresistance
Dudás, J., Ladányi, A., Ingruber, J., Steinbichler, T. B., & Riechelmann, H. (2020) · Cells · doi:10.3390/cells9020428 · Cited by 213
Cancer-Associated Fibroblasts Provide a Stromal Niche for Liver Cancer Organoids That Confers Trophic Effects and Therapy Resistance
Liu, J., Li, P., Wang, L., Li, M., Ge, Z., Noordam, L., Lieshout, R., Verstegen, M. M. A., Ma, B., Su, J., et al. (2020) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2020.09.003 · Cited by 211
The Role of Inflammation and Inflammatory Mediators in the Development, Progression, Metastasis, and Chemoresistance of Epithelial Ovarian Cancer
Savant, S. S., Sriramkumar, S., & O’Hagan, H. M. (2018) · Cancers · doi:10.3390/cancers10080251 · Cited by 215
Cancer-associated fibroblasts and resistance to anticancer therapies: status, mechanisms, and countermeasures
Feng, B., Wu, J., Shen, B., Jiang, F., & Feng, J. (2022) · Cancer Cell International · doi:10.1186/s12935-022-02599-7 · Cited by 218
Integrin Signaling in Cancer Cell Survival and Chemoresistance
Aoudjit, F., & Vuori, K. (2012) · Chemotherapy Research and Practice · doi:10.1155/2012/283181 · Cited by 217
CCL5 promotes breast cancer recurrence through macrophage recruitment in residual tumors
Walens, A., DiMarco, A. V., Lupo, R., Kroger, B. R., Damrauer, J. S., & Alvarez, J. V. (2019) · eLife · doi:10.7554/elife.43653 · Cited by 205
Exosomes in development, metastasis and drug resistance of breast cancer
Yu, D., Wu, Y., Shen, H., Lv, M., Chen, W., Zhang, X., Zhong, S., Tang, J., & Zhao, J. (2015) · Cancer Science · doi:10.1111/cas.12715 · Cited by 208
Activation of IL-6R/JAK1/STAT3 Signaling Induces De Novo Resistance to Irreversible EGFR Inhibitors in Non–Small Cell Lung Cancer with T790M Resistance Mutation
Kim, S. M., Kwon, O.-J., Hong, Y. K., Kim, J. H., Solca, F., Ha, S., Soo, R. A., Christensen, J. G., Lee, J. H., & Cho, B. C. (2012) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-12-0311 · Cited by 203
Exosomal Wnt-induced dedifferentiation of colorectal cancer cells contributes to chemotherapy resistance
Hu, Y.-H., Yan, C. Y. I., Mu, L., Mi, Y., Zhao, H., Hu, H., Li, X., Tao, D.-D., Wu, Y., Gong, J., et al. (2018) · Oncogene · doi:10.1038/s41388-018-0557-9 · Cited by 206
Leukemia Propagating Cells Rebuild an Evolving Niche in Response to Therapy
Duan, C.-W., Shi, J., Chen, J., Wang, B., Yu, Y.-H., Qin, X., Zhou, X.-C., Cai, Y.-J., Li, Z.-Q., Zhang, F., et al. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.04.015 · Cited by 198
Targeting CAFs to overcome anticancer therapeutic resistance
Saw, P. E., Chen, J., & Song, E. (2022) · Trends in cancer · doi:10.1016/j.trecan.2022.03.001 · Cited by 206
Therapy resistance mediated by exosomes
Steinbichler, T. B., Dudás, J., Skvortsov, S., Ganswindt, U., Riechelmann, H., & Skvortsova, I. (2019) · Molecular Cancer · doi:10.1186/s12943-019-0970-x · Cited by 191
The Role of STAT3 in Non-Small Cell Lung Cancer
Harada, D., Takigawa, N., & Kiura, K. (2014) · Cancers · doi:10.3390/cancers6020708 · Cited by 195
A narrative review of tumor-associated macrophages in lung cancer: regulation of macrophage polarization and therapeutic implications
Sedighzadeh, S. S., Khoshbin, A. P., Razi, S., Keshavarz‐Fathi, M., & Rezaei, N. (2021) · Translational Lung Cancer Research · doi:10.21037/tlcr-20-1241 · Cited by 190
The anticancer effects of ferulic acid is associated with induction of cell cycle arrest and autophagy in cervical cancer cells
Gao, J., Yu, H., Guo, W., Kong, Y., Gu, L., Li, Q., Yang, S., Zhang, Y., & Wang, Y. (2018) · Cancer Cell International · doi:10.1186/s12935-018-0595-y · Cited by 188
Acquisition of Chemoresistance and EMT Phenotype Is Linked with Activation of the Endothelin A Receptor Pathway in Ovarian Carcinoma Cells
Rosanò, L., Cianfrocca, R., Spinella, F., Di Castro, V., Nicotra, M. R., Lucidi, A., Ferrandina, G., Natali, P. G., & Bagnato, A. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2325 · Cited by 187
Chemoresistance of Cancer Cells: Requirements of Tumor Microenvironment-mimicking In Vitro Models in Anti-Cancer Drug Development
Jo, Y., Choi, N., Kim, K., Koo, H., Choi, J. H., & Kim, H. N. (2018) · Theranostics · doi:10.7150/thno.29098 · Cited by 188
Desmoplasia and Chemoresistance in Pancreatic Cancer
Schober, M., Jesenofsky, R., Faissner, R., Weidenauer, C., Hagmann, W., Michl, P., Heuchel, R. L., Haas, S., & Löhr, M. J. (2014) · Cancers · doi:10.3390/cancers6042137 · Cited by 190
Cancer-Associated Fibroblasts Share Characteristics and Protumorigenic Activity with Mesenchymal Stromal Cells
Borriello, L., Nakata, R., Sheard, M. A., Fernández, G. E., Sposto, R., Malvar, J., Blavier, L., Shimada, H., Asgharzadeh, S., Seeger, R. C., et al. (2017) · Cancer Research · doi:10.1158/0008-5472.can-16-2586 · Cited by 184
A senescence secretory switch mediated by PI3K/AKT/mTOR activation controls chemoprotective endothelial secretory responses.
Bent, E. H., Gilbert, L. A., & Hemann, M. T. (2016) · Genes & Development · doi:10.1101/gad.284851.116 · Cited by 179
Tumors on chips: oncology meets microfluidics
Włodkowic, D., & Cooper, J. M. (2010) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2010.08.016 · Cited by 183
Mesenchymal Stem Cells Promote Formation of Colorectal Tumors in Mice
Tsai, K., Yang, S., Lei, Y., Tsai, C., Chen, H., Hsu, C., Chen, L., Wang, H., Miller, S. A., Chiou, S., et al. (2011) · Gastroenterology · doi:10.1053/j.gastro.2011.05.045 · Cited by 178
Application of Evolutionary Principles to Cancer Therapy
Enríquez‐Navas, P. M., Wojtkowiak, J. W., & Gatenby, R. A. (2015) · Cancer Research · doi:10.1158/0008-5472.can-15-1337 · Cited by 175
Self-citation
Drug resistance in multiple myeloma: latest findings and new concepts on molecular mechanisms
Abdi, J., Chen, G., & Chang, H. (2013) · Oncotarget · doi:10.18632/oncotarget.1497 · Cited by 172
Microenvironment drug resistance in multiple myeloma: emerging new players
Marzo, L. D., Desantis, V., Solimando, A. G., Ruggieri, S., Annese, T., Nico, B., Fumarulo, R., Vacca, A., & Frassanito, M. A. (2016) · Oncotarget · doi:10.18632/oncotarget.10849 · Cited by 175
Beyond matrix stiffness: targeting force-induced cancer drug resistance
Kalli, M., Poskus, M. D., Stylianopoulos, T., & Zervantonakis, I. K. (2023) · Trends in cancer · doi:10.1016/j.trecan.2023.07.006 · Cited by 185
Tissue-Dependent Tumor Microenvironments and Their Impact on Immunotherapy Responses
Oliver, A. J., Lau, P. K. H., Unsworth, A., Loi, S., Darcy, P. K., Kershaw, M. H., & Slaney, C. Y. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00070 · Cited by 169
Microfluidics Enabled Bottom-Up Engineering of 3D Vascularized Tumor for Drug Discovery
Agarwal, P., Wang, H., Sun, M., Xu, J., Zhao, S., Liu, Z., Gooch, K. J., Zhao, Y., Lu, X., & He, X. (2017) · ACS Nano · doi:10.1021/acsnano.7b00824 · Cited by 168
β1 Integrin Targeting Potentiates Antiangiogenic Therapy and Inhibits the Growth of Bevacizumab-Resistant Glioblastoma
Carbonell, W. S., DeLay, M., Jahangiri, A., Park, C. C., & Aghi, M. K. (2013) · Cancer Research · doi:10.1158/0008-5472.can-13-0011 · Cited by 163
The Selective Tie2 Inhibitor Rebastinib Blocks Recruitment and Function of Tie2Hi Macrophages in Breast Cancer and Pancreatic Neuroendocrine Tumors
Harney, A. S., Karagiannis, G. S., Pignatelli, J., Smith, B. D., Kadioglu, E., Wise, S., Hood, M. M., Kaufman, M. D., Leary, C. B., Lu, W.-P., et al. (2017) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-17-0241 · Cited by 162
Cancer invasion and resistance: interconnected processes of disease progression and therapy failure
Alexander, S., & Friedl, P. (2011) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2011.11.003 · Cited by 159
Protein Kinase C-β-Dependent Activation of NF-κB in Stromal Cells Is Indispensable for the Survival of Chronic Lymphocytic Leukemia B Cells In Vivo
Lutzny‐Geier, G., Köcher, T., Schmidt‐Supprian, M., Rudelius, M., Klein‐Hitpaß, L., Finch, A. J., Dürig, J., Wagner, M. M., Haferlach, C., Kohlmann, A., et al. (2013) · Cancer Cell · doi:10.1016/j.ccr.2012.12.003 · Cited by 164
Carcinoma-Associated Fibroblasts Are a Promising Therapeutic Target
Togo, S., Polanska, U. M., Horimoto, Y., & Orimo, A. (2013) · Cancers · doi:10.3390/cancers5010149 · Cited by 162
The Microenvironment of Lung Cancer and Therapeutic Implications
Mittal, V., Rayes, T. E., Narula, N., McGraw, T. E., Altorki, N. K., & Barcellos‐Hoff, M. H. (2015) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-24932-2_5 · Cited by 154
Evolutionary Approaches to Prolong Progression-Free Survival in Breast Cancer
Silva, A. S., Kam, Y., Khin, Z. P., Minton, S. E., Gillies, R. J., & Gatenby, R. A. (2012) · Cancer Research · doi:10.1158/0008-5472.can-12-2235 · Cited by 152
Self-citation
Cytokine-chemokine network driven metastasis in esophageal cancer; promising avenue for targeted therapy
Bhat, A. A., Nisar, S., Maacha, S., Carneiro-Lobo, T., Akhtar, S., Siveen, K. S., Wani, N. A., Rizwan, A., Bagga, P., Singh, M. K., et al. (2021) · Molecular Cancer · doi:10.1186/s12943-020-01294-3 · Cited by 145
Current diagnostics and treatment of fibrosarcoma -perspectives for future therapeutic targets and strategies
Augsburger, D., Nelson, P. J., Kalinski, T., Udelnow, A., Knösel, T., Hofstetter, M. M., Qin, J. W., Wang, Y., Gupta, A. S., Bonifatius, S., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.20136 · Cited by 144

Authors: Meads, M. B., Gatenby, R. A., & Dalton, W. S.
Affiliations: Moffitt Cancer Center (US)
Corresponding author: Dalton, William S.
ORCID: Meads, Mark B.
Gatenby, Robert A.
Dalton, William S.
Venue: Nature Reviews Cancer
Publisher: Springer Science and Business Media LLC
Published: 2009-08-20
Volume: 9
Issue: 9
Pages: 665-674
ISSN: 1474-175X (ISSN-L)
1474-1768
DOI: 10.1038/nrc2714
OpenAlex: W2066616821
Cited by: 892
References: 109
Citations by year: 2026: 33 · 2025: 44 · 2024: 35 · 2023: 55 · 2022: 54 · 2021: 74 · 2020: 65 · 2019: 58 · 2018: 56 · 2017: 52 · 2016: 68 · 2015: 61 · 2014: 64 · 2013: 51 · 2012: 52
FWCI: 3.53
Type: journal article
Language: en
Open access: closed
Licence: www.springer.com/tdm (tdm)
www.springer.com/tdm (vor)
Locations: Nature reviews. Cancer (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Oncology › Cancer Cells and Metastasis
Health Sciences › Medicine › Hematology › Acute Lymphoblastic Leukemia research
Health Sciences › Medicine › Oncology › Drug Transport and Resistance Mechanisms
Keywords: tumor microenvironment, minimal residual disease, recurrence, acquired drug resistance, stromal factors, adjuvant therapy, cancer therapy resistance
MeSH terms: Humans, Neoplasms, Signal Transduction, Stromal Cells, Neoplasm, Residual, Drug Resistance, Neoplasm

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Environment-mediated drug resistance: a major contributor to minimal residual disease

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks